**Suppl 1.** Descriptive summary of patient factors by infection event level, using random effects model.

| **Variable statistic or category** | **Infection** | **No infection** | **P value** |
| --- | --- | --- | --- |
| Sex |  |  |  |
| Male | 47 (65.3%) | 54 (68.4%) | 0.6763 |
| Female | 25 (34.7%) | 25 (31.6%) |  |
| Age group |  |  |  |
| 0-2 years | 11 (15.3%) | 19 (24.1%) | 0.3349 |
| 2-12 years | 26 (36.1%) | 32 (40.5%) |  |
| 12-16 years | 16 (22.2%) | 13 (16.5%) |  |
| 16-21 years | 19 (26.4%) | 15 (19.0%) |  |
| Ethnicity |  |  |  |
| Hispanic | 49 (68.1%) | 47 (59.5%) | 0.5601 |
| White | 13 (18.1%) | 21 (26.6%) |  |
| Middle Easterner | 6 (8.3%) | 8 (10.1%) |  |
| Asian | 3 (4.2%) | 3 (3.8%) |  |
| Not otherwise specified | 1 (1.4%) | 0 (0.0%) |  |
| Year of transplant |  |  |  |
| 2008 | 11 (15.3%) | 6 (7.6%) | 0.1219 |
| 2009 | 8 (11.1%) | 16 (20.3%) |  |
| 2010 | 11 (15.3%) | 7 (8.9%) |  |
| 2011 | 8 (11.1%) | 14 (17.7%) |  |
| 2012 | 1 (1.4%) | 7 (8.9%) |  |
| 2013 | 5 (6.9%) | 7 (8.9%) |  |
| 2014 | 4 (5.6%) | 3 (3.8%) |  |
| 2015 | 8 (11.1%) | 3 (3.8%) |  |
| 2016 | 6 (8.3%) | 8 (10.1%) |  |
| 2017 | 10 (13.9%) | 8 (10.1%) |  |
| Diagnosis code[1] |  |  |  |
| AL | 41 (56.9%) | 40 (50.6%) | 0.8053 |
| MDS/MPL | 1 (1.4%) | 1 (1.3%) |  |
| PI | 7 (9.7%) | 10 (12.7%) |  |
| IDM | 1 (1.4%) | 1 (1.3%) |  |
| HD | 2 (2.8%) | 3 (3.8%) |  |
| BMF | 9 (12.5%) | 8 (10.1%) |  |
| HGP | 3 (4.2%) | 6 (7.6%) |  |
| CL | 5 (6.9%) | 6 (7.6%) |  |
| PLD | 1 (1.4%) | 0 (0.0%) |  |
| LYMPH | 0 (0.0%) | 3 (3.8%) |  |
| Solid Tumor | 1 (1.4%) | 0 (0.0%) |  |
| Other (Multiple) | 1 (1.4%) | 1 (1.3%) |  |
| Diagnosis code (recategorized) |  |  |  |
| No malignancy | 20 (28.6%) | 25 (32.1%) | 0.6338 |
| Malignancy | 50 (71.4%) | 53 (67.9%) |  |
| Missing | 2 | 1 |  |
| Cell source |  |  |  |
| Cord | 34 (47.2%) | 33 (41.8%) | 0.7920 |
| PBSC | 5 (6.9%) | 6 (7.6%) |  |
| Marrow | 33 (45.8%) | 40 (50.6%) |  |
| Donor source |  |  |  |
| MUD | 50 (69.4%) | 45 (57.0%) | 0.1010 |
| Matched related | 16 (22.2%) | 30 (38.0%) |  |
| Haplo related | 6 (8.3%) | 4 (5.1%) |  |
| Engraftment |  |  |  |
| Under 28 | 54 (75.0%) | 58 (73.4%) | 0.4873 |
| 29-42 d | 10 (13.9%) | 10 (12.7%) |  |
| Longer than 42 d | 3 (4.2%) | 1 (1.3%) |  |
| Failure | 5 (6.9%) | 10 (12.7%) |  |
| Disease status |  |  |  |
| CR1 | 26 (36.1%) | 28 (35.4%) | 0.7447 |
| CR2 | 17 (23.6%) | 16 (20.3%) |  |
| CR3 | 4 (5.6%) | 2 (2.5%) |  |
| CR1/MRD+ | 1 (1.4%) | 2 (2.5%) |  |
| CR2/MRD+ | 1 (1.4%) | 0 (0.0%) |  |
| PR | 2 (2.8%) | 3 (3.8%) |  |
| N/A | 18 (25.0%) | 25 (31.6%) |  |
| CR4 | 0 (0.0%) | 2 (2.5%) |  |
| Aplastic | 1 (1.4%) | 0 (0.0%) |  |
| Active disease | 2 (2.8%) | 1 (1.3%) |  |
| Conditioning/TBI |  |  |  |
| Conditioning, but no TBI | 36 (50.0%) | 51 (64.6%) | 0.0770 |
| Conditioning with TBI | 36 (50.0%) | 28 (35.4%) |  |
| Donor CMV |  |  |  |
| Negative | 28 (38.9%) | 33 (41.8%) | 0.3211 |
| Positive | 44 (61.1%) | 44 (55.7%) |  |
| NA | 0 (0.0%) | 2 (2.5%) |  |
| Serology CMV |  |  |  |
| Negative | 24 (33.3%) | 45 (57.0%) | 0.0057 |
| Positive | 48 (66.7%) | 33 (41.8%) |  |
| NA | 0 (0.0%) | 1 (1.3%) |  |
| CMV pair |  |  |  |
| Rec+/Don+ | 30 (41.7%) | 20 (26.3%) | 0.0235 |
| Rec+/Don- | 18 (25.0%) | 12 (15.8%) |  |
| Rec-/Don+ | 14 (19.4%) | 23 (30.3%) |  |
| Rec-/Don- | 10 (13.9%) | 21 (27.6%) |  |
| Missing |  | 3 |  |
| Transplant number |  |  |  |
| 1 | 64 (88.9%) | 69 (87.3%) | 0.5775 |
| 2 | 7 (9.7%) | 10 (12.7%) |  |
| 3 | 1 (1.4%) | 0 (0.0%) |  |

Note: P values obtained through mixed effects logistic regression with a random intercept for patient to account for repeated transplants. [1]Two patients who had multiple diagnoses codes were recategorized as other/multiple.